Australia markets closed

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3400+0.0700 (+5.51%)
At close: 04:00PM EST
1.3300 -0.01 (-0.75%)
After hours: 05:55PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 32.19M
Enterprise value 50.58M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-87.52%
S&P500 52-week change 314.64%
52-week high 331.2400
52-week low 31.1600
50-day moving average 33.2595
200-day moving average 37.1531

Share statistics

Avg vol (3-month) 31.85M
Avg vol (10-day) 3158.89k
Shares outstanding 524.03M
Implied shares outstanding 6N/A
Float 81.09M
% held by insiders 17.83%
% held by institutions 195.96%
Shares short (13 Jan 2022) 4137.43k
Short ratio (13 Jan 2022) 40.21
Short % of float (13 Jan 2022) 4N/A
Short % of shares outstanding (13 Jan 2022) 40.57%
Shares short (prior month 14 Dec 2021) 4100.68k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 0.00%
Operating margin (ttm)-343.61%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)11.82M
Revenue per share (ttm)6.11
Quarterly revenue growth (yoy)92.70%
Gross profit (ttm)-2.32M
Net income avi to common (ttm)-50.3M
Diluted EPS (ttm)-26.0170
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)21.95M
Total cash per share (mrq)1.01
Total debt (mrq)40.34M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.70
Book value per share (mrq)-1.17

Cash flow statement

Operating cash flow (ttm)-40.37M
Levered free cash flow (ttm)N/A